British rare disease specialist Ambrose Healthcare has acquired Dutch biotech AM-Pharma for up to €161 million, adding an enzyme replacement therapy to its pipeline and a development base in Utrecht.
The Swiss pharmaceutical group has agreed to another, deeper ADC partnership with China’s Hansoh Pharma, with potential ...
Following Fresenius’ launch of a €200 million healthcare venture fund in July, we invited Thomas Thestrup, managing director ...
French biotech OSE Immunotherapeutics has reported higher one-year survival rates with two combinations of its cancer vaccine Tedopi compared with chemotherapy alone in a Phase 2 lung cancer trial.
Each month, the European Medicines Agency’s human medicines committee (CHMP) weighs in on which drugs should reach European ...
Oxford-based OMass Therapeutics has raised $310 million (€276 million) in a Series C financing to advance its small-molecule ...
Helping biopharmaceutical innovators build scalable, manufacturable, and commercially viable processes from the start.
Zealand Pharma shares fell about 4% in Thursday trading after new Phase 2 results for its Roche-partnered obesity drug petrelintide showed encouraging weight loss but a modest improvement in blood ...
Paris-based Rivercell has raised $25 million (about €22 million) in seed funding to generate experimental data and build AI ...
French-Belgian biotech Osivax has reported disappointing Phase 2b results for its broad-spectrum influenza vaccine OVX836, ...
Lakefront Biotherapeutics, formerly Galapagos, has sold five preclinical CAR-T assets to Belgian startup Armed Cell ...
Zealand Pharma will pay Generate Biomedicines $30 million (€27 million) upfront to discover protein drugs for obesity and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results